Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma  Mor-Li Hartman, PhD, John Matthew Esposito, BA, Beow Yong.

PublishΕἰλείθυια Βυζάντιος Modified over 5 years ago

Similar presentations

Presentation on theme: "Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma  Mor-Li Hartman, PhD, John Matthew Esposito, BA, Beow Yong."— Presentation transcript:

1 Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma 
Mor-Li Hartman, PhD, John Matthew Esposito, BA, Beow Yong Yeap, ScD, David John Sugarbaker, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 139, Issue 5, Pages (May 2010) DOI: /j.jtcvs Copyright © Terms and Conditions

2 Figure 1 Cisplatin dose-response curves in malignant pleural mesothelioma cell lines. Effect of loss of cell viability detected with different doses of cisplatin (1–500-μmol/L) in 6 malignant pleural mesothelioma cell lines. Results represent mean of at least 3 experiments; bars represent SD. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

3 Figure 2 Sirolimus dose-response curves in malignant pleural mesothelioma cell lines. Effect of loss of cell viability detected with different doses of sirolimus (1–500 nmol/L) and time courses in 6 malignant pleural mesothelioma cell lines. Results represent mean of at least 3 experiments; bars represent SD. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

4 Figure 3 Sirolimus and cisplatin combination in malignant pleural mesothelioma cell lines. A, Effects of loss of cell viability in different malignant pleural mesothelioma cell lines (MS589, MS428, JMN1B, and MS924) with sirolimus (RAP), cisplatin (CIS), combination of both drugs (RAP + CIS), and nontreatment control (CT) of dimethyl sulfoxide vehicle. For each cell line, enlarged figure near each graph shows increased loss of cell viability from both drugs versus cisplatin alone at specific time points. Columns represent mean of 4 wells; bars represent SD. Each P value is presented in box. B, Malignant pleural mesothelioma cell lines MS428, MS924, and H2052 were treated as in part A and photographed 24 hours after drugs were washed out. Original magnification 200×; abbreviations as in part A. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

5 Figure 4 Dephosphorylation of Akt, p70 S6 kinase, and 4E-BP1 after sirolimus and cisplatin combined treatment. Western blot analysis demonstrates phosphorylation status of the Akt/mTOR pathway proteins using specific antibodies (Phospho) against specific phosphorylation sites (I-IV) of the indicated proteins. Column A represents malignant pleural mesothelioma cell line MS428. Column B represents malignant pleural mesothelioma cell line H2052. Both cell lines were treated with sirolimus (R), cisplatin (C), and the combination of both drugs (R + C). Untreated cells in vehicle (dimethyl sulfoxide) were used as control (CT). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

Download ppt "Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma  Mor-Li Hartman, PhD, John Matthew Esposito, BA, Beow Yong."

Similar presentations

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural.

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD suppresses expression of prometastasis phenotypes in malignant pleural.
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Manuel J. Antunes, MD, PhD, DSc 

Manuel J. Antunes, MD, PhD, DSc 
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2  David Mauchley, MD, Xianzhong Meng, MD, PhD, Thomas.

Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2  David Mauchley, MD, Xianzhong Meng, MD, PhD, Thomas.
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells  Y. Linda Wu, Uday Bhanu.

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells  Y. Linda Wu, Uday Bhanu.
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell.

Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell.
Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine–induced injury in human internal thoracic.

Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine–induced injury in human internal thoracic.
Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant.

Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: An in vitro evaluation  Robert B. Cameron, MD, Dongmei Hou, PhD 

Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: An in vitro evaluation  Robert B. Cameron, MD, Dongmei Hou, PhD 
Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage  Steffen.

Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage  Steffen.
Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation  Hongliang Cong, MD,

Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation  Hongliang Cong, MD,
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase.

Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase.
Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer  Hiroyuki.

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer  Hiroyuki.
Elizabeth H. Baldini, MD, MPH, William G. Richards, PhD, Ritu R

Elizabeth H. Baldini, MD, MPH, William G. Richards, PhD, Ritu R

Similar presentations

Ads by Google